Introduction

Personalisation is reshaping wellness retail, and CBD is no exception. In 2026 a number of UK retailers began piloting bespoke in‑store terpene‑blending kiosks that let customers create mix‑your‑own CBD terpene blends on site. Backed by retail‑tech partner Quantic and ISO‑accredited laboratory Phytovista, these pilots combine experiential commerce with robust compliance features such as age‑verification, inventory control and batch‑level COA traceability. The result is a new retail format that aims to deliver transparency and provenance while reducing regulatory risk for merchants.

What's trending

Several developments define this trend in 2026:

• In‑store customisation: kiosks enable customers to tailor terpene profiles and CBD concentrations at the point of sale, creating a sensory and educational retail encounter.
• Tech‑first retail partners: Quantic has emerged as a key POS and retail‑operations supplier, providing inventory, SKU management and checkout flows designed for bespoke formulations.
• Third‑party lab integration: Phytovista, an ISO‑accredited testing provider, is supplying standards and testing protocols so that every custom mix can be assigned a batch identifier and a third‑party Certificate of Analysis (COA).
• COA traceability: pilots are publishing batch‑level COAs or linking them via QR to finished samples so customers can verify terpene and cannabinoid profiles for their bespoke mixes.

Why it matters

This convergence of bespoke retail and formal lab testing matters for three reasons.

• Consumer confidence and transparency. Being able to scan a batch QR code and view an independent COA creates a new level of trust. In an industry where provenance and laboratory data are key purchase drivers, visible COAs meet growing consumer expectations for transparency.
• Regulatory risk management. The kiosks integrate age‑verification and inventory‑tracking capabilities into the point‑of‑sale flow. That helps retailers demonstrate due diligence — showing not just who bought a product, but which specific batch was dispensed — an important ledger if questions arise about compliance or product quality.
• Commercial opportunity. Industry commentary in 2026 positions personalised CBD as a major growth vector: global market estimates around US$20bn in 2026 underpin retailer investments in experiential kiosks and differentiated in‑store services.

Examples from the pilots

Across the pilot sites the technical and operational approaches vary, but common features are emerging:

• Quantic‑powered POS and inventory. Quantic supplies an integrated stack that manages raw terpene vials as inventory items, logs dispensations to a specific batch number and issues a unique batch code for each bespoke bottle. The system also orchestrates staff workflows for kettling, labelling and COA triggers.
• Phytovista COA support. After a bespoke batch is blended, a sampled aliquot can be analysed by Phytovista under pre‑agreed test panels; the lab issues a COA tied to the batch identifier. Where rapid turnaround is required, pilots are using agreed reduced test panels for initial release and full analysis for archival records.
• Age‑verification at the point of formulation. Kiosks require a verified age check before the blending session begins; customer verification data is tokenised and linked to the batch trace, creating an auditable chain without exposing unnecessary personal data.
• Consumer‑facing lab reports. Retailers in the pilot publish COAs on product pages or provide a QR on the finished label that opens the batch report — a practice already in use for pre‑filled products and now extended to bespoke mixes.
• Hardware compatibility. Pilots are also considering final formats for personalised blends. Some customers opt for pre‑filled 10ml amber bottles that they can use sublingually or add to carriers; others prefer filling vape cartridges compatible with popular hardware. For example, industry‑available cartridges and batteries such as the Infused Amphora CBD vape pen cartridge and the CCELL M3 battery (black) are cited in retail briefings as common hardware references for blended vape formats. Retailers also maintain options of buying established pre‑mixed e‑liquids such as Canavape Blue Dream Complete CBD E‑Liquid (1800mg, 50ml) and Canavape Blue Zkittlez Complete CBD E‑Liquid (1800mg, 50ml) as ready alternatives for customers who prefer off‑the‑shelf choices.

Operational and compliance mechanics

From a retail‑ops perspective, these pilots demonstrate how to marry experiential retail with compliance:

• Inventory governance: raw terpene vials and base CBD concentrates are tracked as discrete SKUs with lot numbers; any dispense against a kiosk session decrements stock and creates an auditable dispense record.
• Batch labelling: every finished mix receives a machine‑printed label with batch code, date, SKU and a scannable QR linking to the COA and lab chromatograms.
• COA lifecycle: retailers retain COA PDFs and chromatogram snapshots in their CMS, linked to product pages and to the POS receipt — a step that mirrors existing good‑practice examples where merchants already publish COAs for standard SKUs.
• Staff training and SOPs: robust standard operating procedures govern sanitary handling, mixing tolerances and sample submission to Phytovista so that lab results remain representative and defensible.

Future outlook

Looking ahead, the pilots point to several likely developments:

• Scaling traceability. Batch COA traceability is likely to become table stakes for any retailer offering bespoke blends. Expect tighter integration between POS, lab APIs and consumer portals so lab reports are live and queryable.
• Frictionless verification. Age‑verification will continue to mature — tokenised ID checks and anonymised tokens linked to batch records reduce privacy friction while preserving auditability.
• Regulatory harmonisation. As labs like Phytovista set consensual test panels for blends, retailers will converge on standard reporting templates that are intelligible to consumers and acceptable to compliance officers.
• Commercial models. Retailers will balance experience‑led revenue against the incremental cost of testing. Many pilots are experimenting with service fees or tiered testing (rapid release vs full panel) to manage margins while keeping transparency high.

Conclusion

The 2026 UK pilot programmes demonstrate that personalised CBD retail can be delivered responsibly when technology, laboratory standards and retail operations are thoughtfully combined. Quantic‑powered POS flows and Phytovista COA support show a practical path to experiential commerce without compromising traceability or compliance. For retailers, the imperative is clear: if you offer bespoke blends, make the lab data visible, lock in rigorous age checks and integrate batch traceability into every customer touchpoint. Consumers, increasingly attuned to provenance, are likely to reward that transparency with loyalty and repeat visits — provided merchants maintain disciplined operations and clear lab‑reporting practices.